Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published October 8, 2021 | Supplemental Material
Journal Article Open

SenSARS: A Low-Cost Portable Electrochemical System for Ultra-Sensitive, Near Real-Time, Diagnostics of SARS-CoV-2 Infections

Abstract

A critical path to solving the SARS-CoV-2 pandemic, without further socioeconomic impact, is to stop its spread. For this to happen, pre- or asymptomatic individuals infected with the virus need to be detected and isolated opportunely. Unfortunately, there are no current ubiquitous (i.e., ultra-sensitive, cheap, and widely available) rapid testing tools capable of early detection of SARS-CoV-2 infections. In this article, we introduce an accurate, portable, and low-cost medical device and bio-nanosensing electrode dubbed SenSARS and its experimental validation. SenSARS' device measures the electrochemical impedance spectra of a disposable bio-modified screen-printed carbon-based working electrode (SPCE) to the changes in the concentration of SARS-CoV-2 antigen molecules ("S" spike proteins) contained within a sub-microliter fluid sample deposited on its surface. SenSARS offers real-time diagnostics and viral load tracking capabilities. Positive and negative control tests were performed in phosphate-buffered saline (PBS) at different concentrations (between 1 and 50 fg/mL) of SARS-CoV-2(S), Epstein–Barr virus (EBV) glycoprotein gp350, and Influenza H1N1 M1 recombinant viral proteins. We demonstrate that SenSARS is easy to use, with a portable and lightweight (< 200 g) instrument and disposable test electrodes (< U.S. $5), capable of fast diagnosis (~10 min), with high analytical sensitivity (low limits of detection, LOD = 1.065 fg/mL, and quantitation, LOQ = 3.6 fg/mL) and selectivity to SARS-CoV-2(S) antigens, even in the presence of structural proteins from the other pathogens tested. SenSARS provides a potential path to pervasive rapid diagnostics of SARS-CoV-2 in clinical, point-of-care, and home-care settings, and to breaking the transmission chain of this virus. Medical device compliance testing of SenSARS to EIC-60601 technical standards is underway.

Additional Information

© IEEE 2021. This article is free to access and download, along with rights for full text and data mining, re-use and analysis. Manuscript received June 4, 2021; revised September 13, 2021; accepted September 24, 2021. Date of publication October 8, 2021; date of current version October 21, 2021. This work was supported by the Colombian Ministry of Science, Innovation, and Technology, through the Mincienciatón health emergency under Award 360-2020. The Associate Editor coordinating the review process was Dr. Alessandra Galli. The authors thank Dr. Maria Adelaida Gomez (CIDEIM), Dr. Olga Lucia Agudelo, and Dr. Fernando Rosso (Fundación Valle del Lili) for their instrumental contributions within a broader collaboration on the development and clinical testing of SenSARS, Lina Hermida, Leidi Rojas, Diego López, Paola Mejia, Bleider Arizala, and Christopher Valencia from the Universidad Javeriana, and Mónica Castiblanco, Dr. Luis Hernando Nieto, Luisa Fernanda Cabezas, Dr. Arturo Luna, and Dr. Mabel Torres from the Colombian Ministry of Science, Innovation and Technology for their support.

Attached Files

Supplemental Material - SenSARS_A_Low-Cost_Portable_Electrochemical_System_for_Ultra-Sensitive_Near_Real-Time_Diagnostics_of_SARS-CoV-2_Infections.pdf

Files

SenSARS_A_Low-Cost_Portable_Electrochemical_System_for_Ultra-Sensitive_Near_Real-Time_Diagnostics_of_SARS-CoV-2_Infections.pdf

Additional details

Created:
August 22, 2023
Modified:
October 23, 2023